Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that patients who received Favipiravir treatment after having COVID-19 had lower positive pull test scores for telogen effluvium hair loss compared to those who did not, suggesting that Favipiravir may not influence the development of telogen effluvium.

In this study of non-hospitalized patients in Dubai, pre-COVID vaccination and treatments with favipiravir or sotrovimab were associated with a reduced risk of developing long COVID.

This review concluded that monoclonal antibodies are currently the most effective treatment for COVID-19, with potential efficacy of high-titer convalescent plasma when used early, while multiple other drugs require further evaluation to determine their effectiveness.

This study reports that drug repurposing for COVID-19 has had mixed results, with success for some drugs but a lack of clinical efficacy for others, highlighting the need for improved preclinical profiling and a standardized drug development platform for future antiviral treatments.

This review summarizes 25 small molecule drugs with in vitro and in vivo data for COVID-19 treatment, highlighting their structural diversity and potential to guide future antiviral discovery.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

This study observed that late seniors and men are more susceptible to severe COVID-19 infections, with diabetes identified as the most common comorbidity linked to severe symptoms and lower lymphocyte levels.

This study observed that in COVID-19 patients at Zahirah General Hospital, older men with diabetes were more prone to severe symptoms and had lower lymphocyte levels.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This report documents the first known case of acute inflammatory demyelinating polyneuropathy potentially linked to pegylated interferon-alpha 2a in a woman undergoing treatment for chronic hepatitis C.

This study identified five FDA-approved drugs, including cepharantine and clofazimine, as potential COVID-19 therapies through in silico and in vitro screening targeting viral entry mechanisms.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This review discusses the potential of organoids in modeling COVID-19 disease and developing therapies, without reporting new results, and highlights opportunities and challenges in their application for research.

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

This source explores long COVID syndrome and identifies risk factors like older age, female gender, and comorbidities such as diabetes. It mentions potential diagnostic biomarkers, highlights ongoing clinical trials, and emphasizes the importance of vaccines and rehabilitation in managing long COVID.

This study found that telogen effluvium, a type of hair loss, was prevalent among 24% of COVID-19 patients, likely triggered by stress and medication related to the illness.

This review discusses gene polymorphisms in COVID-19 patients but reports no new clinical findings.

This review details various skin manifestations linked to COVID-19 and highlights dermatitides caused by personal protective equipment, emphasizing the need for accurate diagnosis and prompt treatment.

This review outlines drug repurposing as an efficient, low-cost strategy to identify new uses for existing drugs, highlighting various computational and experimental approaches as well as publicly available databases to aid in personalized pharmacotherapy.

This review examines various skin conditions associated with the COVID-19 pandemic, covering virus-related dermatoses and cutaneous side effects from treatments and vaccines, but reports no clinical results.

This article reviews the structure, genomic organization, and pathogenesis of SARS-CoV-2 and discusses current efforts in prevention and treatments for COVID-19 without reporting new clinical results.

This study reports an increase in the frequency and variety of skin conditions associated with COVID-19, noting that milder cases often present with pernio-like lesions, while severe cases may involve livedo racemosa, retiform purpura, and acral ischemia.

This study concludes that one year after COVID-19 infection, patients in Northeast Brazil showed improvements in quality of life, although some symptoms such as anxiety and memory loss persisted.

This review discusses mucocutaneous manifestations associated with Covid-19, classifies the lesions, and describes their characteristics and treatments but reports no new clinical findings.

This review found that while many medicinal plants show potential antiviral and other therapeutic effects against COVID-19 based on prior studies, more rigorous clinical trials are needed to confirm their efficacy and safety.

This review summarizes literature and experiences on the skin manifestations in COVID-19 patients, suggesting some may help identify asymptomatic cases, but it reports no new clinical results.

This report describes a severe COVID-19 case in a patient with SLE and nephritis, where hydroxychloroquine improved outcomes after regular use.

This case report describes a patient with SLE and COVID-19, where hydroxychloroquine showed a favorable impact on the virus when taken regularly, leading to clinical improvement and discharge after 24 days.